Stem cells and their progeny constitute a potential resource for replacing damaged tissues or supplying missing functions, but also pose a threat of aberrant behavior, including neoplastic growth or immunopathology. Suicide genes introduced into these cells before transplantation might provide a means of addressing this threat by permitting the ablation of the cells if they subsequently misbehave. Retroviral transduction of the E. coli gpt and herpes thymidine kinase (HSVtk) suicide genes was used to determine the degree to which stem cells could be sensitized to the prodrugs 6-thioxanthine (6TX) and ganciclovir (GCV) respectively, and whether this sensitivity could persist over many cell generations. The ES-E14TG2a murine embryonic stem cell line
Introduction
Stem cells are a focus of growing scientific interest as a potential source of transplantable cells to regenerate missing or damaged tissues or to supply functions lacking in individuals with acquired or inherited disorders. Much attention has been devoted to embryonic stem cells because of their ability to differentiate along multiple lineages, but recent interest has also embraced stem cells committed to specific lineages, such as hematopoietic, mesenchymal, or neural stem cells. This interest has been reinforced by evidence that lineage commitment is not invariably fixed, but can in some cases shift from one lineage to another, given an appropriate extracellular environment. 1 The potential value of transplanting stem cells or tissues derived from them carries with it a potential risk. During the lifetime of the individual who receives them, some may misbehave. The misbehavior could take various forms -malignancy in any tissue that retains growth potential, immune pathology on the part of lymphocytes, or hyperfunction on the part of cells intended to supply a
was rendered sensitive to quantitative ablation at prodrug concentrations well tolerated by untransduced cells (50 M 6TX, 1 g/ml GCV). The HSVtk gene also conferred GCV sensitivity on human mesenchymal stem cells and hematopoietic precursors derived from the murine cells, although ablation was not complete. Because ES-E14TG2a cells are deficient in the cellular enzyme HPRT, they are sensitive to hypoxanthine/aminopterin/thymidine (HAT). This property enhanced the persistence of chemosensitivity in gpt-transduced cells by permitting cells that lost 6TX sensitivity to be ablated with HAT.
Gene Therapy (2002) 9, 955-962. doi:10.1038/sj.gt.3301771 missing function at regulated levels (eg hyperinsulinemia from insulin-secreting cells). The aberrant cell or cells might arise during the establishment of transplantable cell lines or during their rapid in vitro growth to desired numbers. Particular concerns may apply to embryonic stem cells because of evidence for their epigenetic instability. 2 Additionally, aberrant cells could arise after transplantation at any time during the life of the host, and might simply reflect the occasional mishaps that can afflict any cell in a human host, whether transplanted or native.
Even though transplanted cells might misbehave for reasons shared with endogenous tissues, their temporary residence outside the body provides an opportunity to confer on them a protection less easily afforded to endogenous tissues -the introduction of suicide genes that would allow the cells to be destroyed if they later exhibited undesirable properties. The concept of introducing suicide genes into cells pre-emptively (ie before unwanted properties developed) was first suggested in 1968 3 and led to the development of an antitumor strategy entailing the introduction of the herpes simplex virus thymidine kinase (HSVtk) gene into cells to sensitize them to destruction by the guanosine analog ganciclovir (GCV). 4 Many investigators have subsequently explored the HSVtk/GCV combination as a therapeutic modality rather than a pre-emptive one, but its pre-emptive properties have been demonstrated in a murine model involving premalignant mammary epithelial cells. 5 More recently, the pre-emptive use of HSVtk has been introduced into human clinical trials by investigators who infused HSVtk transduced donor lymphocytes into patients who had received bone marrow transplants for leukemia from allogeneic donors. 6 The lymphocytes were given for their antileukemic effects, but patients who developed graft-versus-host disease (GVHD) -a serious complication of lymphocyte infusions -were treated with GCV to destroy the offending lymphocytes. Initial reports indicate successful amelioration of GVHD in most patients, but also indicate a need to further optimize the system in terms of lymphocyte function, as well as suicide gene efficacy and persistence. 7, 8 In the work reported here, we have asked two questions: can stem cells be sensitized by retroviral transduction to prodrugs that can later be used to destroy them, and can a means be found to ensure the persistence of chemosensitivity in these cells over the course of many cell generations? In addressing the latter question, we have utilized a strategy for maintaining chemosensitivity that entails the combination of suicide gene transduction with endogenous gene loss, as we reported previously for other cell types. 9 Briefly, the first layer of sensitivity is achieved by selecting cells with natural mutations for loss of either cellular hypoxanthine-guanine phosphoribosyltransferase (HPRT) or cellular thymidine kinase (cell-TK, not to be confused with HSVtk). Such cells are sensitive to destruction by a HAT regimen (hypoxanthine/aminopterin/thymidine) because to circumvent aminopterin toxicity, a cell must possess both HPRT to utilize the hypoxanthine and a thymidine kinase to utilize the thymidine. Furthermore, although cells deficient in either function are viable in the absence of HAT, some cell types grow at reduced rates. 10 In the case of HPRT-deficient cells, the second layer of sensitivity, as well as a restoration of growth is achieved by replacing HPRT with the E. coli gpt gene, a suicide gene that sensitizes cells to 6-thioxanthine (6TX). 11 In the case of cells deficient in cell-TK, the missing function is replaced with HSVtk, which sensitizes to GCV. As a consequence of these substitutions, cells require two independent processes to lose all chemosensitivity. One is the loss of the inserted suicide gene or its expression -an event that returns the cell to a state of HAT sensitivity and possibly a reduced growth rate. The second is the loss of HAT sensitivity, which is itself a rare event. Although HAT is most commonly used in vitro, we have reported the successful use of an in vivo HAT regimen to treat transplanted murine myelomas deficient in HPRT. 12 The majority of studies reported here were conducted with murine embryonic stem cells, and a smaller number with human mesenchymal stem cells. We utilized the murine cells because human embryonic stem cells have not been available to us. In addition, the availability of a murine embryonic stem cell line, ES-E14TG2a, that had previously been selected for HPRT-deficiency 13 permitted us to examine the consequences of replacing HPRT with the gpt suicide gene, as outlined above.
Results
The gpt gene sensitizes embryonic stem cells to 6TX Consistent with the lack of a gpt transgene, parental ESE14TG2a cells (hereafter referred to as ES cells) were found to be resistant to 6TX at concentrations as high as 100 M, whereas none of these cells survived exposure to a regimen selective for gpt-expressing cells -mycophenolic acid/xanthine/hypoxanthine (MXH).
14 As expected from their HPRT-negative status, the cells also exhibited a stable HAT-sensitive phenotype, with no survivors observed among 3.6 × 10 7 cells exposed to this regimen. We constructed a retroviral gpt vector, MSCVgpt (Figure 1 ), based on a Moloney murine leukemia virus backbone modified for improved expression in murine embryonic stem cells. 15 MSCVgpt transduction rendered ES cells highly sensitive to 6TX (Figure 2 ), with only a minority of cells surviving at 2 M. This sensitivity Results are shown for 6TX at 50 M, and for GCV at 1 g/ml, except for the granulocyte/macrophage colonies, which were exposed to 0.5 g/ml. See equaled or exceeded the sensitivities we have observed previously in a study of gpt-transduced murine sarcoma cells. 11 Even at high concentrations (50 M), a small number of viable survivors were observed, but these did not grow out on replating. As expected, the transduced cells were resistant to MXH. They were also moderately resistant to HAT. Even after multiple passages in MXH, however, their resistance to HAT toxicity remained incomplete (survival 71.8 ± 3.1% of control values), suggesting that gpt expression adequate to confer high sensitivity to 6TX does not necessarily permit the cells to fully circumvent an aminopterin-induced inhibition of nucleic acid synthesis. Table 1 We tested the growth rate of ESgpt cells by harvesting triplicate cultures at 24, 48 and 72 h after plating and calculating doubling times from the 24-48 and 48-72-h
Figure 3 Sensitivity of HSVtk-transduced and untransduced murine embryonic stem cells to GCV. Viable cell numbers measured in four or more replicate wells 7 days after drug addition are expressed as percent of control cultures without drug (mean + s.e.).
Gene Therapy intervals. In non-selective medium, these cells grew faster than the parental ES cells, with doubling times (mean ± s.e.) of 21.9 ± 4.4 h compared with 34.0 ± 3.1 h for ES cells. It remains to be determined whether this is a general feature of gpt transduction or specific to the ESgpt subline. Nevertheless, the result is consistent with an ability of the gpt gene to play a growth-supporting role that is absent from the parental cells because of their HPRT deficiency.
To examine the stability of the 6TX sensitive phenotype, ESgpt cells were grown in the absence of MXH selection for approximately 100-120 cell generations over 16 weeks. At this point, retesting demonstrated a sensitivity profile that was unchanged at low drug concentrations, but also demonstrated a substantial increase in the number of survivors (17 ± 4% of control values in duplicate cultures) at the highest concentration tested, 50 M. Furthermore, in contrast to the population maintained in selective medium, the surviving cells grew out on replating and were completely insensitive to 50 M 6TX upon re-exposure. Southern blotting (Figure 2 ) revealed the absence of sequences hybridizing with a 32 Plabeled gpt probe, in contrast to the expected 0.7 kb band observed in DNA from the 6TX sensitive ESgpt cells, implicating deletion of the gpt gene as the presumptive mechanism for the loss of 6TX sensitivity.
Cells that lose 6TX sensitivity acquire HAT sensitivity
When the cells selected for 6TX resistance were exposed to HAT or MXH, they proved to be uniformly sensitive. In the presence of HAT, no surviving cells were detectable from among 1.2 × 10 4 cells derived from an additional eight generations in drug-free medium beyond the initial 100-120, and fewer than 1% of cells survived in MXH. The acquisition of HAT sensitivity in conjunction with 6TX resistance provides support for a major element of the rationale underlying these experiments; viz the creation of stable chemosensitivity based on the expectation that gpt transduction into HPRT-negative stem cells will confer a suicide function (6TX sensitivity) that is not only moderately stable in its own right, but is replaced with a different suicide function (HAT sensitivity) if the original suicide gene is lost or unexpressed.
The HSVtk gene sensitizes embryonic stem cells to GCV As shown in Figure 3 , HSVtk transduction sensitized ES cells to GCV in a dose-related manner. The observed level of sensitivity is similar to that reported for numerous other HSVtk transduced cell types. 5, 16, 17 Unlike some other cell types, however, even untransduced ES cells exhibited observable cytotoxicity at the higher range of GCV doses tested -1 and 5 g/ml. This observation suggests that if HSVtk transduction is used to impart chemosensitivity to transplanted cells, even cells that lose the transduced gene might respond at least partially to GCV therapy. To date, and in contrast to the gpt transduced cells that accumulated some 6TX resistant mutants over time, we have not observed cells resistant to 1 or 5 g/ml GCV after passages of ESTK cells in the absence of selection for more than 300 cell generations. However, based on experience with other HSVtk transduced cells and with retroviral transduction in general, it seems likely that continued passage without selection would eventually yield some GCV-resistant mutants. In contrast to gpt transductants, which grew faster than their parental counterparts, ESTK cells grew at a rate that was slightly (although not significantly) slower than that of parental ES cells, as well as more variable (doubling time 37.2 ± 16.7 h versus 34.0 ± 3.1 h for ES cells). The lack of a growth-stimulatory effect is not unexpected, since ES cells already exhibit TK activity mediated by their native cell-TK gene.
Differentiated ESTK cells are GCV-sensitive
ESTK cells were induced to differentiate first to embryoid bodies and then to granulocyte/macrophage progenitors. As shown in Figure 4 , exposure to 0.5 g/ml GCV at this point resulted in a substantial reduction in colonies. A lesser but still demonstrable GCV effect on colony formation was also observed with untransduced ES cells, simi- lar to observations noted above with undifferentiated cells. In the absence of GCV, ESTK cells formed fewer colonies than their untransduced counterparts, suggesting a lesser growth potential for these cells -a possibility also noted above for undifferentiated ESTK cells. 4, 17, 18 A bystander effect has also been observed with the gpt gene. 11 In contrast, little or no bystander effect was demonstrable in the present study with either HSVtk or gpt transduced ES cells, even when they comprised 50% of the mixture. Thus, 6TX treatment of duplicate mixtures of untransduced/gpt-transduced cells reduced cell counts to 39 ± 6% of untreated controls -a result not statistically distinguishable from the 50% value expected from the killing of only the transduced component of the mixture. Similarly, GCV treatment of an untransduced/HSVtk-transduced mixture reduced cell numbers to 32 ± 4%. This result is consistent with a small bystander effect, but could also reflect merely the killing of transduced cells combined with the slight cytotoxicity that GCV exerts on untransduced cells as noted above. Interpretation of the lack of prominent bystander effects in the present study must be qualified by the observation that suspensions of these cells dispersed by trypsinization frequently contain small clusters, as well as single cells, thereby making it difficult to create a homogeneous mixture of two different cell populations.
Transduced embryonic stem cells exhibit minimal if any bystander effect
Many studies have demonstrated that GCV treatment of untransduced cells mixed with even a small number of HSVtk transduced cells can result in extensive destruction of the untransduced cells -a so-called 'bystander effect' thought to be mediated by transfer of phosphorylated GCV via gap junctions and probably by other mechanisms as well.
Human mesenchymal stem cells (HMSC) can be sensitized to GCV by HSVtk
As shown in Figure 5 , HSVtk transduction sensitized HMSC cells to GCV, but the degree of sensitization was less than that observed with the murine embryonic stem cells. One third of the cells survived at the highest GCV concentration employed (10 g/ml); higher concentrations were not tested because they are unlikely to be therapeutically relevant in vivo. Because survival measurements do not completely define drug effects, duplicate cultures of HMSC-TK cells surviving 10 g/ml GCV were replated in a separate experiment, and exhibited a plating efficiency of 3.6 ± 0.3%. Untreated cells exhibited a replating efficiency of 15.1 ± 5.3%, suggesting that cells that survive GCV are impaired in their growth potential. Even in the absence of manipulations, HMSC cells grow slowly, with further reductions and eventual growth cessation on continued passage -a property that may account for the lesser sensitivity of HSVtk transduced HMSC cells to GCV, a prodrug that depends on DNA synthesis for its toxicity.
Discussion
The studies reported here demonstrate that stem cellsboth murine and human -can be sensitized by suicide genes to prodrugs that can later be used to destroy them. The level of sensitivity achieved is comparable to, or in some cases greater than that achievable in a variety of other cell types. It is achievable with both the wellcharacterized HSVtk/GCV combination and with the combination of the E. coli gpt gene and the xanthine analog 6TX. While most pronounced in rapidly growing murine embryonic cells, it is also retained in these murine cells after they have begun to differentiate along hematopoietic lines. It is also apparent to a lesser degree in human stem cells already committed to mesenchymal lineages at the time of suicide gene transduction.
Our results are consistent with the possibility that concomitant with differentiation, stem cells require higher GCV doses than undifferentiated cells to exhibit equivalent cytotoxicity, but this comparison is complicated by differences in experimental conditions and by differences between murine and human cells. Whether a lesser GCV sensitivity, if real, reflects a slower rate of cell growth, a reduction in gene expression consequent to differentiation, or some other property of the cells remains to be determined. As a practical matter, it appears to coincide with a reduction in the in vitro growth potential of the cells as they approach a complete loss of their ability to proliferate. If further experience identifies a potential for cells in this state to pose a threat in vivo (eg hyperfunction), suicide genes such as HSVtk or gpt may be less appropriate than those capable of converting prodrugs into alkylating agents or other moieties that kill non-proliferating cells. [19] [20] [21] [22] An interesting property of the parental (ie untransduced) murine embryonic stem cells tested in this study appears to be an inherent sensitivity to GCV at a level, that while much less than exhibited by HSVtk transduced cells, is nevertheless greater than that observed for most other HSVtk negative cell types in many previous studies, including our own. 4, 5 This sensitivity is apparent at GCV concentrations that are achievable clinically, and suggests that even cells that have lost HSVtk might respond to GCV to some extent. Another mechanism for eliminating HSVtk-negative cells, 'bystander effects', was not demonstrable in our system. To some extent, this may reflect the technical difficulty of creating homogeneous mixtures from two different populations of ES cells, because even well-trypsinized suspensions of these cells harbor frequent clusters of up to four to five cells. On the other hand, it is likely that the differentiation status of cells affects their ability to participate in bystander effects. Consequently, effects that are not demonstrable in undifferentiated cells might become apparent in their differentiated progeny. Bystander effects mediated by metabolites that cannot cross cell membranes by diffusion, such as phosphorylated GCV, appear to involve mechanisms that include gap junctional communication, and a similar mechanism might be expected to apply to the gpt/6TX system, which also involves a phosphorylated derivative. The gap junctional status of embryonic stem cells has not been well defined. Communication evidenced by dye transfer has been observed, 23 but mice deficient in gap junctional communication or the connexins that mediate it have been reported to develop normally except for cardiac defects, suggesting that extensive gap junctional communication may not play a prominent role in early stages of embryogenesis. 23, 24 If a suicide gene is to be introduced into cells preemptively to permit the later eradication of those cells after an interval that might span many cell generations, an essential requirement is stability; the cells must remain chemosensitive at the end of the interval. The availability of the HPRT-negative ES-E14TG2a embryonic stem cell line permitted us to test the possibility that replacement of the HPRT gene by the gpt gene could create a cell population that could not easily shed all forms of chemosensitivity. The gpt-transduced cells exhibited remarkable 6TX sensitivity, but after 100-120 doublings in the absence of selection, a fraction of the population became 6TX-resistant. In the process, however, this fraction was rendered susceptible to destruction by HAT. The consequence of this linkage was a stable form of chemosensitivity in which one suicide function, if lost, was replaced by another. We have previously reported with other cell types, and with both the HSVtk/GCV and gpt/6TX systems that the frequency of obtaining cells that lose both forms of chemosensitivity varies from about 10 Ϫ11 to 10 Ϫ9 , and can probably be reduced even further by selection for the most stable HPRT-negative or cell-TK-negative sublines. 9 Evidence from clinical studies has demonstrated the feasibility of employing regimens equivalent to HAT in cancer patients (reviewed in Ref. 25) . Typically, the antifolate component of the regimen is a high dose of methotrexate rather than aminopterin, followed after an interval by thymidine 'rescue'. Hypoxanthine is omitted because normal plasma levels of this purine are adequate to obviate a need for an exogenous source. Unlike the rationale for the work reported here, which requires HPRT-negative cells as the starting point for transduction, the clinical regimens have not addressed the HPRT status of cancer cells, which are likely to share the HPRT-positive phenotype of the tissues from which they are derived. 26 As a consequence, clinical benefits have been limited mainly to protection against methotrexate toxicity rather than enhanced antitumor efficacy.
When the gpt and HSVtk genes are compared, each exhibits potential advantages for pre-emptive stem cell transduction. The degree of prodrug sensitivity achievable with HSVtk is greater than that conferred by gpt in these cells or any other reported cell type. On the other hand, transduction with gpt, unlike HSVtk, does not require addition of a selectable marker such as the neo gene, because gpt transductants can be selected with MXH. A further advantage of gpt is related to our reported strategy of enhancing the stability of chemosensitivity by combining suicide gene transduction with endogenous gene loss. For gpt, this requires preselection for cells lacking cellular HPRT to serve as targets for transduction. These are not infrequent, because the X chromosomal location of the HPRT gene dictates that only a single copy of the gene must experience an inactivating mutation to render a cell HPRT-deficient. In contrast, the use of HSVtk requires preselection for cells deficient in cell-TK. Such cells are more rare, because the autosomal location of the cell-TK gene requires that both alleles be inactivated to render a cell TK-deficient.
An issue not addressed in this work, but relevant to pre-emptive use of transduced cells is a need to avoid immune rejection resulting from expression of the transgene. This phenomenon has been observed in some, 27, 28 but not in other studies 5, 29 involving the transplantation of HSVtk transduced cells into immunocompetent hosts. Approaches to this issue are likely to include attempts to steer immune responses in the direction of tolerance, gene expression that is inducible rather than constitutive, and the use of suicide genes of mammalian rather than prokaryotic origin. 19, 20, 22 Although the current work has focused on stem cells, the principles it embodies apply to other transplantable cell types. These include autologous cells removed from the body for transduction with a therapeutic gene and then reintroduced into their host, and, once transplantation barriers and safety concerns are surmounted, xenografts. In the latter case, the suicide genes could be used to create transgenic animals as the source of the grafts. Ultimately, results in humans of attempts to eradicate transplanted cells will indicate whether similar introduction of suicide genes into endogenous tissues as a protection against later aberrant behavior is worth exploring, when technology permits.
Materials and methods

Cell cultures
The HPRT-deficient murine embryonic stem cell line ESE14TG2a (ES cells) was obtained from the American Type Culture Collection (Rockville, MD, USA), and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose and supplemented with 100 M 2-mercaptoethanol, 100 U/ml penicillin/100 g/ml streptomycin, and 15% fetal bovine serum (FBS). For maintenance of ES cells in the undifferentiated state, leukemia inhibitory factor was added (ESGRO; Gibco/BRL, Rockville, MD, USA) at 10 Ϫ3 units/ml. PT67 retroviral packaging cells (Clontech, Mountain View, CA, USA) were cultured in DMEM with 10% FBS and penicillin/ streptomycin. Normal human mesenchymal stem cells (HMSC) capable of chondrogenic, adipogenic and osteogenic differentiation were obtained from BioWhittaker (Rockland, ME, USA) and cultured in proprietary medium from that supplier.
Retroviral vectors
Both the gpt and HSVtk vectors ( Figure 1 ) were constructed from the pMSCVneo plasmid (Clontech). 15 MSCV (murine stem cell virus) vectors differ from standard Moloney murine leukemia virus vectors in possessing altered LTRs and tRNA primer binding sites that enhance transcription and reduce the binding of suppressive factors in murine embryonic stem cells. To construct pMSCVgpt, a XhoI-ClaI fragment from pZIP-V-GPT containing the gpt coding region 11 was inserted into pMSCVneo that had been digested with XhoI and ClaI to remove the neo gene and its associated PGK promoter. To construct pMSCVneoTK, a BamHI-ClaI fragment from plasmid pTK (15) 30 containing the HSVtk promoter and coding region was inserted into pMSCVneo digested with BamHI and ClaI. Producer cells were created by selecting PT67 cells resistant to 0.8 mg/ml G418 after transfection with the pMSCVneoTK plasmid, or after cotransfection of the pMSCVgpt plasmid together with pSV2neo (American Type Culture Collection). Flasks with multiple colonies were used as a source of producer cells.
Transduction of stem cells
To obtain transductants, the DMEM medium in which producer cells were maintained was replaced with the growth medium appropriate for ES or HMSC cells, as described above, for 1 day. Supernatants from the cultures were then passed through 0.45 m filters and added to cultures of ES or HMSC cells in the presence of 2 g/ml polybrene on a slowly rocking platform at 37°C for 3-6 h. HSVtk transductants were selected with 0.8 mg/ml G418. Gpt transductants were selected in medium containing a combination of 19.5 M mycophenolic acid, 1.6 mM xanthine, and 100 M hypoxanthine. This regimen is lethal to wild-type cells, but is tolerated by cells expressing gpt, because the product of this gene, xanthine-guanine phosphoribosyltransferase (XGPRT), enables the cells to utilize the xanthine to circumvent a mycophenolic acid-induced block in guanine nucleotide synthesis; hypoxanthine aids selection, probably by inhibiting guanine salvage pathways.
14 Cells that survived this selection were further selected by passage through medium containing HAT. In some cases, to protect against revertants, they were subsequently maintained in medium containing 78 M mycophenolic acid plus xanthine and hypoxanthine as described above. This combination is referred to as MXH. Other cultures were passaged in the absence of selective medium to determine the stability of their drug sensitivity profile over time. In initial testing, cells from two different ES cultures selected for gpt transduction exhibited similar 6TX sensitivities, and two different cultures selected for HSVtk transduction exhibited similar GCV sensitivities. In each case, one of the two isolates was then used for further characterization.
Drug sensitivity testing
In most experiments, wells of a 24-well plate (15.6 mm well diameter) were seeded with 6.3 × 10 3 cells in 0.9 ml medium, followed 18-20 h later by addition of drugs in 0.1 ml medium to final concentrations ranging from 0.01 to 5 g/ml for GCV and 2 to 100 M for 6TX (the use of g/ml to describe GCV concentrations is designed for consistency with previous reports by us and others; 1 g/ml is approximately 3.9 M). After 6 days (gpt-transduced cells) or 7 days (HSVtk-transduced cells), the cultures were harvested by trypsinization, and viable cells were enumerated in a hemocytometer on the basis of erythrosin dye exclusion. In the case of HMSC cells, we were unable to harvest viable cells quantitatively by trypsinization. Viability was therefore measured by means of a metabolic assay employing dimethylthiazolyl-diphenyltetrazolium (MTT), obtained from Sigma (St Louis, MO, USA) and used according to the supplier's instructions. HMSC cells were exposed to GCV in concentrations ranging from 0.5 to 10 g/ml for 18 days. This interval was dictated by preliminary observations indicating that transduced cell numbers in GCV-treated cultures were still declining at earlier time points (7 and 12 days) and reflects the slow growth of these cells. MTT assay results were recorded as spectrophotometric readings at 570 nm after subtraction of background readings at 660 nm.
Bystander assays
Suspensions containing either parental ES cells, gpt or HSVtk-transduced ES cells, or a 50:50 mixture of parental and transduced cells were plated as described above. Drug sensitivity tests were then conducted as described, utilizing 100 M 6TX for the studies with gpt transductants and 0.2 g/ml GCV for the HSVtk transductants.
Granulocyte/macrophage colony formation
Iscove's medium (IMDM), FBS, methycellulose, trypsin/EDTA, and other additives were purchased from StemCell Technologies, Vancouver, British Columbia (www.stemcell.com) except as noted, and were used according to the supplier's instructions. Briefly, embryonic stem cells were passed into predifferentiation medium consisting of IMDM-15% FBS containing 100 M monothioglycerol (Sigma) and penicillin/streptomycin, and additionally supplemented with 2 mM L-glutamine, 0.1 mM non-essential amino acids, and ESGRO (10 Ϫ3 units/ml, Gibco/BRL). After 3 days, they were plated into 35-mm petri dishes in methylcellulose primary differentiation medium (IMDM with final concentration of 0.81% methylcellulose, 13.5% FBS, 135 M monothioglycerol, 36 ng/ml murine stem cell factor, and 1.8 mM added L-glutamine). Ten days later, the resulting embryoid bodies were harvested and dispersed by trypsinization, and the suspension was replated in 2 ml aliquots containing 2-3 × 10 4 cells into 35-mm petri dishes in hematopoietic differentiation medium (IMDM with final concentration of 0.45% methylcellulose, 13.5% FBS, 135 M monothioglycerol, 145 ng/ml murine stem cell factor, 90 g/ml insulin (Sigma), and 4 ng/ml murine GM-CSF (Sigma). After 3 days to permit the hematopoietic differentiation process to begin, 0.1 ml of IMDM with or without 100 g/ml GCV was added dropswise, and granulocyte/macrophage colonies were scored after an additional 7 days.
DNA analysis DNA isolated from cultured cells using a Genomic DNA Kit (Qiagen, Valencia, CA, USA) was subjected to PCR (GeneAmp 9700, PE Applied Biosystems, Norwalk, CT, USA) to amplify a 712-bp sequence within the gpt gene using forward primer 5'-TTA GTG CGC CAG ATC TCT ATA ATC-3' and reverse primer 5'-CGG ACT AGC CTC GAG GTT TCA GGA-3'. After 30-45 cycles, reaction products were electrophoresed and subjected to Southern blotting by standard methods, 31 using a 32 P-labeled probe consisting of a 950-bp XhoI-ClaI restriction fragment from pMSCVgpt containing the gpt coding region and encompassing the PCR-amplified sequences. Autoradiography of the blots using an intensifying screen was performed briefly (Ͻ10 min) at room temperature, or Ϫ80°C for intervals up to 72 h when needed to confirm the absence of signals.
